SEATTLE, Jan. 14 /PRNewswire/ -- Patients undergoing in vitro fertilization self-administer daily injections of progesterone from two to eight weeks after the egg retrieval procedure. The outcome of a new study of an investigational formulation of progesterone could replace these painful intramuscular injections of progesterone in oil with less painful subcutaneous injections.
Seattle Reproductive Medicine (SRM), along with eight other large fertility centers across the country, has been selected to participate in a study designed to compare the safety and effectiveness of an investigational aqueous formulation of progesterone that will be compared to a form of progesterone administered intra-vaginally.
"For years patients have complained about these injections. One shot may be tolerable, but many weeks of daily injections is a long time for this degree of discomfort," says Dr. Michael Soules, MD, SRM's managing partner. Dr. Soules is the principle investigator for the U.S. arm of this study. He adds, "Being a large practice affords us the opportunity to make these types of studies available to our patients. These studies help patients offset the cost of their treatment."
Progesterone supplementation is routinely given after egg recovery for two weeks or longer to assist embryo implantation and support of the uterine lining. Progesterone in oil injected intramuscularly is the usual means of administration. These self-administered injections can be quite painful. The drug being tested is a new formulation of an existing approved medication. If outcome, tolerability and safety are the same or better with the investigational formulation of progesterone then patients would no longer be subjected to these drugs.
Study participants must be in an IVF cycle and will receive study related medications valued near $300 at no cost and a $1500 payment for participation. Enrollment in the study is now open and patients interested in participating should contact Seattle Reproductive Medicine for more information.
About Seattle Reproductive Medicine
Seattle Reproductive Medicine is led by a nationally recognized team of seven physicians who offer comprehensive, state-of-the-art assistance for couples with infertility and women with reproductive endocrine problems. Drs. Soules and Klein have received several National Institutes of Health (NIH) research grants over the years and the Clinic's work in reproductive aging has received prominent media coverage in Seattle. Seattle Reproductive Medicine is a member of IntegraMed, an exclusive network of 140 physicians and scientists limited to the highest performing infertility practices. One of every five procedures in the United States is performed in an IntegraMed practice. For more information, visit http://www.SeattleFertility.com.
|SOURCE Seattle Reproductive Medicine|
Copyright©2009 PR Newswire.
All rights reserved